An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
NP39488
Phase 2 other active
Quick answer
An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma for Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL) is a Phase 2 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)
- Phase
- Phase 2
- Modality
- other
- Status
- active